It s been a shitty 2016 so far for Theranos: the medical company that claimed to be able to conduct a variety of tests from a single drop of blood had to void results that went back two years after they were found to be inaccurate.
And last month, CEO Elizabeth Holmes was barred from operating labs for the next two years.
So naturally, when the company was slated to make a presentation at an American Association for Clinical Chemistry AACC expo, people expected Theranos to deliver new information about its testing methods.
Instead, Holmes presented a new product called the miniLab, a 95-pound tabletop diagnostic tool for identifying a range of illnesses including Zika, using small samples of blood.
Theranos says that the miniLab consists of a robot that can dynamically perform tasks on samples that traditionally required manual processing, and can communicate remotely with the Theranos Virtual Analyzer to enable interpretation of the results in a lab at another location.
It s hard to say if this is a big win for Theranos.